We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.
Goal: Uncover the function of SLC16A14, a protein uniquely expressed in fibrolamellar carcinoma (FLC) and absent from normal tissues and other cancers Principal Investigator: Avner Schlessinger, PhD Grant length: One year Study overview: Prior FCF-funded research demonstrated that the transporter protein, SLC16A14, is essential for FLC cell survival and appears to be regulated by FLC’s …
Goal: Provide a biological rationale for biomarker-guided testing of antibody drug conjugates in FLC Principal Investigator: Mark Yarchoan, MD Grant length: Six months Study overview: Cancer cells often overexpress many proteins on their surface. Because of these differences, cancer cells can have unique surface “signatures” that can be used to specifically target them with therapies. These molecules can also …
Goal: Use AI-driven drug discovery tools to identify potential binders to the DNAJ-PKAc fusion protein Principal investiogator: Hannes Nissen-Meyer Grant length: One year Study overview: Khumbu proposes to support FLC drug discovery efforts by applying its AI- and quantum mechanics-driven computational platform to identify and optimize small-molecule inhibitors of the DNAJ-PKAc fusion protein, the known …
Goal: To identify and optimize targeted protein degraders that selectively eliminate the cancer-driving DNAJ-PKAc fusion protein in fibrolamellar carcinoma while sparing normal proteins Principal Investigator: Fleur Ferguson, PhD Grant length: Six months Study overview: Dr. Fleur Ferguson (UC San Diego), in collaboration with Dr. Nabeel El-Bardeesy (Massachusetts General Hospital), is exploring whether targeted protein degradation …